News Releases

Date	Title and Summary	View
Apr 17, 2018	Johnson & Johnson Reports 2018 First-Quarter Results: 2018 First-Quarter Sales of $20.0 Billion Increased 12.6% versus 2017 2018 First-Quarter EPS was $1.60 2018 Adjusted First-Quarter EPS of $2.06 increased 12.6%* Sales Momentum Continued in the First Quarter Strong Adjusted EPS Growth of 12.6%* Company Increased Sales and Reaffirms EPS Guidance
Apr 16, 2018	Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases
Apr 12, 2018	INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease New analysis further supports the potential renal protective effects of INVOKANA ® Austin, TX, April 12, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced an additional analysis from the landmark CANVAS Program showing INVOKANA ® (canagliflozin) improved renal
Apr 11, 2018	Johnson & Johnson Vision Announces Revolutionary Contact Lens Innovation with ACUVUE OASYS® with Transitions® Light Intelligent Technology™ Developed in strategic partnership with Transitions Optical, this one-of-a-kind contact lens corrects vision and adapts to changing light conditions
Mar 20, 2018	Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson Joseph Wolk Promoted to Executive Vice President, Chief Financial Officer
Mar 20, 2018	Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
Mar 16, 2018	Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc. NEW BRUNSWICK, N.J. , March 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion , subject to customary adjustments.
Mar 15, 2018	Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
Mar 11, 2018	INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure- Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
Mar 07, 2018	Johnson & Johnson Vision Advocates on Behalf of Patients at FTC Public Workshop Company emphasizes the importance of balancing policies that promote eye health alongside patient access and encouraging competition in the marketplace